GSK Logo

site-logo

Are you a Healthcare Professional? Visit the Healthcare Professional website.

Tyverb

lapatinib

Product Overview

What is HER2 positive metastatic breast cancer?

Breast cancer with HER2 receptors is called HER2 positive breast cancer. HER2 receptors tell the cancer to grow. Advanced and metastatic are the names used when cancer has spread beyond the original cancer site.

What is Tyverb?

Tyverb is a tablet medicine. It can slow down or stop the growth of advanced or metastatic HER2 positive breast cancers.

How does Tyverb work?

Tyverb blocks the HER2 receptors from signalling the cancer to grow.

How is Tyverb taken?

Tyverb is prescribed with another medicine, usually Xeloda® (also known as 'capecitabine') or an aromatase inhibitor, Aromatase inhibitor drugs are called Femara® (also known as letrozole), Arimidex® (also known as anastrozole) or Aromasin® (also known as exemestane)

Tyverb is only prescribed by a doctor after a number of thorough checks and is not suitable for all patients.   

For further information on Tyverb please see:

Tyverb 250mg film-coated tablets Patient Information Leaflet (PIL)

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Tyverb® is a trade mark of the GlaxoSmithKline group of companies.

Rate the usefulness of this page

Rollover stars, click to select, then press submit.

Xeloda® is a trade mark of Roche Products Limited
Femara® is a trade mark of Novartis Pharmaceuticals Corporation
Arimidex® is a trade mark of AstraZeneca Limited
Aromasin® is a trade mark of Pfizer Inc.

S.S: Last updated 22 March 2013: UK/LPD/0027/13

Links & Resources

GSK does not recommend, endorse or accept liability for sites controlled by third-parties.